Thrombosis Update最新文献

{"title":"Sex differences in clinical characteristics, management, and outcomes in patients with venous thromboembolism in the direct oral anticoagulant era: Insight from the COMMAND VTE Registry-2","authors":"Takahiro Kuno ,&nbsp;Norimichi Koitabashi ,&nbsp;Yugo Yamashita ,&nbsp;Takeshi Morimoto ,&nbsp;Yoshiaki Ohyama ,&nbsp;Noriaki Takama ,&nbsp;Masaru Obokata ,&nbsp;Ryuki Chatani ,&nbsp;Kazuhisa Kaneda ,&nbsp;Yuji Nishimoto ,&nbsp;Nobutaka Ikeda ,&nbsp;Yohei Kobayashi ,&nbsp;Satoshi Ikeda ,&nbsp;Kitae Kim ,&nbsp;Moriaki Inoko ,&nbsp;Toru Takase ,&nbsp;Shuhei Tsuji ,&nbsp;Maki Oi ,&nbsp;Takuma Takada ,&nbsp;Kazunori Otsui ,&nbsp;Takeshi Kimura","doi":"10.1016/j.tru.2025.100229","DOIUrl":"10.1016/j.tru.2025.100229","url":null,"abstract":"<div><h3>Introduction</h3><div>Sex-specific differences in the prognosis of venous thromboembolism (VTE) remain controversial, particularly in the current era of widespread use of direct oral anticoagulants. Real-world management and outcomes of VTE stratified by sex were investigated in a nationwide registry.</div></div><div><h3>Methods</h3><div>The COMMAND VTE Registry-2 is a multicenter registry that enrolled 5197 consecutive acute symptomatic VTE patients from 31 centers in Japan between January 2015 and August 2020. In this cohort, baseline characteristics, anticoagulation strategies, and long-term clinical outcomes were compared between men and women. Multivariable Cox proportional hazards models were used to estimate adjusted hazard ratios for clinical outcomes.</div></div><div><h3>Results</h3><div>The study population consisted of 2134 men (41.1 %) and 3063 women (58.9 %). Compared with women, men were younger (mean age ± standard deviation, 66.1 ± 14.7 vs. 68.9 ± 16.2 years, <em>P</em> &lt; 0.001), more frequently had active cancer (31.1 % vs. 27.6 %, <em>P</em> = 0.006), and were less likely to present with transient risk factors (32.4 % vs. 40.5 %, <em>P</em> &lt; 0.001). Pulmonary embolism was more common in men (56.7 % vs. 51.5 %, <em>P</em> &lt; 0.001). There were no significant differences in the cumulative 5-year incidences of recurrent VTE or major bleeding between men and women (7.3 % vs. 7.8 %, <em>P</em> = 0.77; 10.8 % vs. 12.4 %, <em>P</em> = 0.20). Although the incidence of all-cause death was higher in men (34.5 % vs. 30.6 %, <em>P</em> = 0.02), this difference was not significant after multivariable adjustment (hazard ratio 1.05, 95 % confidence interval 0.94–1.17, <em>P</em> = 0.39).</div></div><div><h3>Conclusion</h3><div>In this large, multicenter registry, sex was not associated with recurrent thrombosis, major bleeding, or long-term mortality after multivariable adjustment.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"21 ","pages":"Article 100229"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiphospholipid antibodies and psyche","authors":"Emmanouil S. Papadakis,&nbsp;Lucy A. Norris","doi":"10.1016/j.tru.2025.100231","DOIUrl":"10.1016/j.tru.2025.100231","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"21 ","pages":"Article 100231"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145789743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombophilia in women undergoing medically assisted reproduction – prevalence and clinical consequence","authors":"Jesper Strandberg ,&nbsp;Anne-Mette Hvas ,&nbsp;Jurgita Janukonyté ,&nbsp;Søren Risom Kristensen ,&nbsp;Ulrik Schiøler Kesmodel ,&nbsp;Anette Tarp Hansen","doi":"10.1016/j.tru.2025.100222","DOIUrl":"10.1016/j.tru.2025.100222","url":null,"abstract":"<div><h3>Introduction</h3><div>In Denmark, 10 % of new-borns are being conceived with the aid of medically assisted reproduction (MAR). MAR can imply induction of high levels of oestradiol, which in turn leads to increased coagulation activity, decreased natural anticoagulant activity, and reduced fibrinolytic activity. Venous thromboembolism (VTE) is therefore a feared complication, especially in women with other risk factors for VTE, such as family history of VTE, previous VTE, or thrombophilia. Thrombophilia screening is advised in women with clinical risk factors of VTE prior to undergoing MAR. Women with thrombophilia should be handled according to current thrombosis prophylaxis guidelines.</div></div><div><h3>Aim</h3><div>The aim of this study was to investigate the prevalence of thrombophilia in women undergoing MAR compared to the general population, to get an overview of the clinical consequences for women with thrombophilia, and to ensure that the national recommendations regarding thrombophilia screening, are being complied with.</div></div><div><h3>Materials and methods</h3><div>A total of 160 women referred from three public fertility clinics, from 1 May 2015 to 1 May 2020, for thrombophilia investigation prior to MAR, were included. Thrombophilia analyses included both the genetic factors and acquired factors.</div></div><div><h3>Results</h3><div>A higher prevalence of heterozygous factor V Leiden (14 %) and protein S deficiency (2 %) was found in our study population as compared with the general Western population.</div></div><div><h3>Conclusion</h3><div>We found a higher prevalence of some thrombophilias in women referred to MAR.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100222"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National and regional incidence patterns of venous thromboembolism in Finland during 1998–2021 with corresponding mortality trends in 1998–2019","authors":"Lasse Myllylahti ,&nbsp;Jari Haukka ,&nbsp;Eero Hirvensalo ,&nbsp;Riitta Lassila","doi":"10.1016/j.tru.2025.100207","DOIUrl":"10.1016/j.tru.2025.100207","url":null,"abstract":"<div><h3>Objectives</h3><div>Previous research suggest that venous thromboembolism (VTE) -related mortality have been declining over the recent decades, despite the increasing trend of pulmonary embolism (PE) incidence. There is evidence of some regional differences in VTE incidence. We wanted to evaluate the national and regional 21st century VTE incidence in Finland, as well as respective national VTE mortality trends.</div></div><div><h3>Patients and methods</h3><div>In this nationwide registry study, anonymous participants were patients with VTE diagnoses (I26 or I80) during hospital visits or VTE-related documentation of primary cause of death. To assess incidence, we recorded VTE-related hospital visits from the HILMO registry of the Finnish Institute for Health and Welfare. To assess mortality, we recorded deaths with a VTE diagnosis as a primary cause of death from the registries of Statistics Finland. Additionally, we acquired the data about pulmonary CT angiographies from STUK, which is the radiation and nuclear safety authority in Finland.</div></div><div><h3>Results</h3><div>At the national level, the PE incidence doubled during the study period, while the incidence rates of deep vein thrombosis remained stable. Some regional variances in VTE incidence were encountered. The usage of radiological examinations to diagnose PE have become more frequent during the study period. The mortality for VTE peaked in 2004, following the clear declining trend during the follow-up period.</div></div><div><h3>Conclusion</h3><div>Despite the remarkable increase in PE incidence, the mortality rates have been constantly declining from 2004. These results are valuable for the future epidemiological research of VTE.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100207"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144605752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes of direct oral anticoagulant off-label dosing in nonvalvular atrial fibrillation","authors":"M. Jansson ,&nbsp;S. Själander ,&nbsp;V. Sjögren ,&nbsp;F. Björck ,&nbsp;H. Renlund ,&nbsp;A. Själander","doi":"10.1016/j.tru.2025.100210","DOIUrl":"10.1016/j.tru.2025.100210","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Introduction&lt;/h3&gt;&lt;div&gt;Direct oral anticoagulants (DOACs) used in nonvalvular atrial fibrillation (NVAF) are superior or non-inferior to warfarin in reducing the risk of stroke while at the same time having a similar or lower risk of bleeding. However, reduced doses are prescribed more often than expected from clinical practice and off-label underdosing is a frequent issue. The objective of this study was to compare effectiveness and safety between guideline and off-label dosing of DOACs.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Materials and methods&lt;/h3&gt;&lt;div&gt;Auricula, a Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 47,355 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) after exclusion of 92,316 patients due to concomitant venous thromboembolism, previous mechanical heart valve (MHV) or previous data entry in Auricula. The median durations of follow up were 403, 419, 373 and 209 days in the on-label standard dose cohort, off-label reduced dose cohort, on-label reduced dose cohort and the off-label standard dose cohort respectively. Endpoints (stroke and major bleeding) and baseline characteristics were collected from hospital administrative registers using ICD-10 codes or the Swedish Stroke register. Cohorts were compared using weighted adjusted Cox regression after full optimal matching based on propensity scores.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Off-label underdosing of DOACs (n = 6,187, 9.7 %) was associated with higher risk of major bleeding HR 1.16 (95 % CI 1.05–1.27), other bleeding HR 1.16 (1.04–1.30), myocardial infarction HR 1.47 (1.20–1.80), ischemic stroke HR 1.25 (1.04–1.50) and all-cause mortality HR 1.52 (1.37–1.69) compared to on-label standard dosing (n = 35,065, 55.2 %). Among off-label underdosed DOACs, dabigatran was associated with higher risk of all-cause stroke 1.86 (1.07–3.23), ischemic stroke HR 1.97 (1.10–3.52) and all-cause stroke and systemic embolism HR 1.92 (1.11–3.32) compared to apixaban. Rivaroxaban was associated with major bleeding HR 1.70 (1.41–2.03), gastrointestinal bleeding HR 1.92 (1.33–2.77), and other bleeding HR 1.97 (1.57–2.47) compared to apixaban. The study could not show any differences comparing off-label overdosing of DOACs and on-label reduced dosing, besides lower risk of all-cause mortality HR 0.69 (0.52–0.93) in the overdosed patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;In this large observational registry-based NVAF cohort, underdosing of DOACs is associated with higher risk of ischemic and all-cause stroke but also major bleeding when compared to on-label dosing. Underlying DOAC therapy may need to be tailored to the specific patient when choosing off-label reduced dosing since underdosed rivaroxaban is associated with higher risk of bleeding complications, and underdosed dabigatran is associated with higher risk of stroke complications, when comparing both with apixaban.&lt;/div&gt;&lt;/d","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100210"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The risk of venous thromboembolism behind bars","authors":"Lucy A. Norris,&nbsp;Emmanouil S. Papadakis (Editors in chief)","doi":"10.1016/j.tru.2025.100224","DOIUrl":"10.1016/j.tru.2025.100224","url":null,"abstract":"","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100224"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145104417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring experiences of patients attending an outpatient thrombosis service in Canada","authors":"Gabriela Carrillo-Balam ,&nbsp;Tiffany Lee ,&nbsp;Stephanie Young","doi":"10.1016/j.tru.2025.100218","DOIUrl":"10.1016/j.tru.2025.100218","url":null,"abstract":"<div><h3>Background</h3><div>There is limited information on patients' experiences that influence their satisfaction and perception of the quality of care received at comprehensive thrombosis and anticoagulation management services. However, in order to provide patient-centred care, patients’ input is fundamental. Therefore, we aimed to explore the views and experiences of people who received care at an Adult Outpatient Thrombosis Service to identify aspects that are valued as well as areas for improvement.</div></div><div><h3>Methods</h3><div>This is an analysis of free-text data from an anonymous survey sent to all adult patients who received care from a multidisciplinary Thrombosis Service in Newfoundland and Labrador, Canada between October 2017 and May 2019. Thematic analysis was used to analyze the open-ended free text responses and identify common themes.</div></div><div><h3>Findings</h3><div>In total, 40.7 % (n = 229) of survey respondents (N = 563) provided comments to the free-text question. Respondents made more positive comments than negative comments. Four common themes were identified: feeling seen, heard, and cared for; the information received filled the gap and sometimes missed the mark; service organization and follow-up: smooth for some, frustrating for others; and, accessing care: virtual options, travel burden, and waiting.</div></div><div><h3>Conclusion</h3><div>This analysis highlights the positive effect of receiving clear information and having a respectful patient-provider relationship on patients' perceived quality of care. Conversely, the need for alternative consultation-delivery modes, such as virtual care, was identified as an area of opportunity to improve patients’ care experience.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100218"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144653780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombin generation remains stable in frozen plasma over long-term storage","authors":"A. Carlo ,&nbsp;R. de Laat-Kremers ,&nbsp;B. de Laat ,&nbsp;M. Ninivaggi","doi":"10.1016/j.tru.2025.100216","DOIUrl":"10.1016/j.tru.2025.100216","url":null,"abstract":"<div><h3>Background</h3><div>The ST Genesia is a fully automated thrombin generation (TG) device. Measuring TG can be useful for medical purposes as it is an indicator for the bleeding or thrombotic risk of a patient. When measuring TG, it is of utmost importance to be careful with the preanalytical part as it can affect TG. One of the preanalytical steps to be cautious with, is the plasma sample storage temperature and duration.</div></div><div><h3>Methods</h3><div>Citrated blood was collected and centrifuged twice for 10 min at 2840g to obtain platelet poor plasma. Plasma samples were stored directly in the freezer either at −20 °C or at −80 °C. TG was measured with a low, intermediate and high tissue factor concentration (STG-BleedScreen, STG-ThromboScreen and STG-DrugScreen, respectively) in fresh samples and after storage at -20°C and -80°C for 1 day, 1 month, 3 months, 6 months and 12 months. The samples stored at −80 °C were also measured after 18 and 24 months.</div></div><div><h3>Results</h3><div>Freezing platelet poor plasma samples did affect the TG parameters. This observation was independent of the storage temperature and the tissue factor used for triggering TG. Interestingly, TG was not significantly affected by time in storage at −20 °C and −80 °C even up to one year or two years, respectively. Some variation was observed in the samples measured with thrombomodulin, which may have been due to the use of a reagent kit with different lot number.</div></div><div><h3>Conclusion</h3><div>Freezing plasma does affect TG independently of the storage temperature. However, once frozen, the TG does not vary significantly in time even up to one or two years for samples stored at −20 °C and −80 °C, respectively.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100216"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144653781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospitalizations for bleeding associated with apixaban versus rivaroxaban according to dose in Medicare beneficiaries","authors":"Luke S. Vest ,&nbsp;Seo H. Baik ,&nbsp;Fitsum Baye ,&nbsp;Kin-Wah Fung ,&nbsp;Clement J. McDonald","doi":"10.1016/j.tru.2025.100220","DOIUrl":"10.1016/j.tru.2025.100220","url":null,"abstract":"<div><h3>Introduction</h3><div>Apixaban and rivaroxaban are the most prescribed direct oral anticoagulants, and the safety of different doses in patients at high risk for bleeding is not fully defined. The objective of this study was to compare the rate of hospitalizations due to bleeding in patients prescribed apixaban versus rivaroxaban at specific doses.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of more than 1.9 million Medicare beneficiaries who filled prescriptions for apixaban or rivaroxaban from 2014 to 2020 using the Medicare Parts A, B, C and D encounter and prescription claims database. The primary outcomes measured were hospitalizations due to bleeding categorized by location (intracranial, gastrointestinal [GI], and other) and all-cause mortality.</div></div><div><h3>Results</h3><div>Among the population studied, 1,022,170 (53 %) filled a prescription for apixaban 5 mg during the study period, followed by rivaroxaban 20 mg (27 %) and rivaroxaban 10 mg (11 %). Compared to the reference group of apixaban 5 mg, combination prescriptions for rivaroxaban 15–20 mg were associated with more than twice the risk of hospitalization due to GI bleeding (hazard ratio [HR] = 2.41, 95 % confidence interval [CI]: 2.15–2.70) and other bleeding (HR = 2.42, 95 % CI: 1.92–3.05) and were associated with a 51 % higher risk of hospitalization due to intracranial bleeding (HR = 1.51, 95 % CI: 1.15–1.98). There were 88,740 (4.6 %) deaths during the study period, with a 27 % increased risk of death associated with prescriptions for apixaban 2.5 mg (HR = 1.27, 95 % CI: 1.24–1.30) and a 19 % decreased risk of death associated with prescriptions for rivaroxaban 10 mg (HR = 0.81, 95 % CI: 0.78–0.85).</div></div><div><h3>Conclusion</h3><div>Rivaroxaban doses of 15 mg and greater were associated with higher bleeding risk. This data may aid clinicians in making an informed decision when prescribing specific doses of apixaban and rivaroxaban, particularly for patients with a high risk of bleeding.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100220"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144852853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterizing anticoagulation reversal practices in Colombia: Initial insights from a national registry","authors":"Sebastián Seni-Molina ,&nbsp;Santiago Posso Marín ,&nbsp;Juan Esteban Masmela ,&nbsp;María Camila Naranjo-Ramírez ,&nbsp;Arturo D. Mora ,&nbsp;Juliana María Gutiérrez-Posso ,&nbsp;Julio Diez-Sepúlveda ,&nbsp;Juan David Victoria-Salcedo ,&nbsp;Ana Cristina Montenegro Arenas ,&nbsp;Camilo Andrés Rueda Ortiz ,&nbsp;Edgar David Gómez Lahitton ,&nbsp;Hoover O. León-Giraldo ,&nbsp;Juan Esteban Gómez-Mesa ,&nbsp;On behalf of the RECCANT-AR Research Group","doi":"10.1016/j.tru.2025.100215","DOIUrl":"10.1016/j.tru.2025.100215","url":null,"abstract":"<div><h3>Background</h3><div>Anticoagulation reversal is critical in emergency settings for patients experiencing anticoagulant-related bleeding or requiring invasive or surgical procedures. Despite its importance, evidence in Colombia is limited.</div></div><div><h3>Methods</h3><div>RECCANT-AR (<strong><em>Re</em></strong><em>gistro</em> <strong><em>C</em></strong><em>olombiano de</em> <strong><em>C</em></strong><em>línicas de</em> <strong><em>Ant</em></strong><em>icoagulación y el Uso de</em> <strong><em>A</em></strong><em>gentes</em> <strong><em>R</em></strong><em>eversores</em>) is a multicenter, observational, ambispective study analyzing anticoagulated patients requiring reversal therapy due to bleeding or procedural needs. Data from the first 144 patients across four institutions were analyzed to describe their sociodemographic and clinical profiles.</div></div><div><h3>Results</h3><div>The cohort had a mean age of 66.9 years (SD ± 15.3) and a nearly equal sex distribution. Ethnicity was predominantly Mestizo (67.5%), followed by White (17.5%) and Afrodescendant (13.3%). The most common comorbidities were hypertension (61.8%), previous venous thromboembolism episodes (31.3%), dyslipidemia (30.6%), and diabetes mellitus (21.5%). Warfarin was the predominant anticoagulant (84%), followed by apixaban (4.9%) and dabigatran (4.2%). Bleeding was the primary indication for reversal (92.4%), while surgical needs accounted for 7.6% of cases. The most used reversal agents were vitamin K (75%) and prothrombin complex concentrates (27.1%). Hospitalization was required in 82% of cases, with 55.1% admitted to intensive care. The mortality rate was 7.6%.</div></div><div><h3>Conclusion</h3><div>Our study is the first multicenter characterization of anticoagulated patients requiring reversal therapy in Colombia. Cardiovascular comorbidities were highly prevalent, highlighting their association with hemorrhagic complications. Bleeding was the leading indication for reversal, and warfarin the most used anticoagulant, likely reflecting its higher bleeding risk. The limited availability of direct oral anticoagulant-specific reversal agents remains a challenge. The high hospitalization and mortality rates underscore the high-risk nature of this population, emphasizing the need for improved access to reversal agents and optimized anticoagulation practices. Further research is warranted.</div></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":"20 ","pages":"Article 100215"},"PeriodicalIF":0.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144766902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}